Atypical Hemolytic Uremic Syndrome: Update on the Complement System and What Is New

Patricia Hirt-Minkowski, Michael Dickenmann, Jürg A. Schifferli

Divisions of Transplantation Immunology and Nephrology, and Internal Medicine, University Hospital Basel, Basel, Switzerland

Key Words
Hemolytic uremic syndrome · Complement system · Complement C3 · Complement factor H · Factor I · Factor B · Membrane cofactor protein (CD46) · Plasma therapy · Transplantation

Abstract
Atypical hemolytic uremic syndrome (aHUS) is a rare disease of microangiopathic hemolytic anemia, thrombocytopenia, and predominant renal impairment. It is characterized by the absence of Shiga toxin-producing bacteria as a triggering factor. During the last decade, aHUS has been demonstrated to be a disorder of the complement alternative pathway dysregulation, as there is a growing list of mutations and polymorphisms in the genes encoding the complement regulatory proteins that alone or in combination may lead to aHUS. Approximately 60% of aHUS patients have so-called ‘loss-of-function’ mutations in the genes encoding the complement regulatory proteins, which normally protect host cells from complement activation: complement factor H (CFH), factor I (CFI) and membrane cofactor protein (MCP or CD46), or have ‘gain-of-function’ mutations in the genes encoding the complement factor B or C3. In addition, approximately 10% of aHUS patients have a functional CFH deficiency due to anti-CFH antibodies. Recent advances in understanding the pathogenesis of aHUS have led to a revised classification of the syndrome. Normal plasma levels of CFH and CFI do not preclude the presence of a mutation in these genes. Further, genotype-phenotype correlations of aHUS have clinical significance in predicting renal recovery and transplant outcome. Therefore, it is important to make a comprehensive analysis and perform genetic screening of the complement system in patients with aHUS to allow a more precise approach, especially before transplantation. This may also provide opportunities for more specific treatments in the near future, as complement inhibition could represent a therapeutic target in these patients who have a considerably poor prognosis in terms of both mortality and progression to end-stage renal disease and a great risk of disease recurrence after transplantation.

Introduction

Thrombotic microangiopathy (TMA) was first described by Symmers [81] in 1952. It has been defined as a histopathological entity of several disorders including the 2 main syndromes, the hemolytic uremic syndrome (HUS) and thrombotic thrombocytopenic purpura (TTP), and a related syndrome that occurs during preg-
nancy, i.e. the hemolysis, elevated liver enzyme, low platelet (HELLP) syndrome. TMA is characterized by the presence of fibrin and/or platelet thrombi in the microcirculation of various organs (fig. 1). The pathophysiology of TMA involves an initial endothelial cell injury induced by various factors and followed by occlusions of small arterioles and capillaries by platelet plugs and/or fibrin thrombi. The common clinical features are microangiopathic hemolytic anemia, thrombocytopenia and variable organ damage. Following the initial description of TTP by Moschcowitz [82] in 1924 and HUS by Gasser and co-workers [83] in 1955, these 2 main syndromes of TMA had for a long time been distinguished considering only clinical aspects: HUS characterized by predominant renal involvement, i.e. acute renal failure, and TTP, of which predominant neurological involvement is a feature. However, the clinical presentation of these disorders can overlap and many factors can trigger HUS such as Shiga toxin (Stx)-producing enterobacteria, especially enterohemorrhagic Escherichia coli serotype 0157:H7 (VTEC/STEC), or in some tropical regions Shigella dysenteriae type 1, which is the most frequent form of HUS, with predominant occurrence in children called typical or postdiarrheal (D+) HUS [1], but also by pneumococcal (via neuraminidase of Streptococcus pneumoniae and T antigen exposure) and human immunodeficiency virus infections, metastatic cancers, organ and stem cell transplantation, autoimmune diseases or drugs and it even occurs without any identifiable trigger [2].

Table 1. Classification [modified from 11]

<table>
<thead>
<tr>
<th>Etiology advanced</th>
<th>Clinical associations: etiology unknown</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 Infection induced</td>
<td>1 Human immunodeficiency virus</td>
</tr>
<tr>
<td>a Stx-producing bacteria; enterohemorrhagic E. coli, S. dysenteriae type 1, Citrobacter</td>
<td>2 Malignancy, cancer chemotherapy and ionizing radiation</td>
</tr>
<tr>
<td>b S. pneumoniae, neuraminidase, and T antigen exposure</td>
<td>3 Calcineurin inhibitors and transplantation</td>
</tr>
<tr>
<td>c Other infectious agents</td>
<td>4 Pregnancy, HELLP syndrome and oral contraceptive pill</td>
</tr>
<tr>
<td>2 Disorders of complement regulation</td>
<td>5 SLE and antiphospholipid antibody syndrome</td>
</tr>
<tr>
<td>a Genetic disorders of complement regulation</td>
<td>6 Glomerulopathy</td>
</tr>
<tr>
<td>b Acquired disorders of complement regulation, for example anti-CFH antibodies</td>
<td>7 Familial, not included in part 1</td>
</tr>
<tr>
<td>3 Von Willebrand proteinase, ADAMTS13 deficiency</td>
<td>8 Unclassified</td>
</tr>
<tr>
<td>a Genetic disorders of ADAMTS13</td>
<td></td>
</tr>
<tr>
<td>b Acquired von Willebrand proteinase deficiency: autoimmune, drug induced</td>
<td></td>
</tr>
<tr>
<td>4 Defective cobalamine metabolism</td>
<td></td>
</tr>
<tr>
<td>5 Drug induced (quinine)</td>
<td></td>
</tr>
</tbody>
</table>

SLE = Systemic lupus erythematosus.

Over the past decade, clinical and basic research has improved our understanding of the pathogenesis of TMA and helped to distinguish HUS from TTP. There have been 2 major breakthroughs. The first was the identification that ADAMTS13 (a disintegrin-like and metalloprotease with thrombospondin type 1 repeats) deficiency is more likely to present with the insidious or fluctuating neurological signs of adult idiopathic TTP [3–6]. But even severe ADAMTS13 deficiency does not account for all cases of idiopathic TTP [7]. The second was the finding that abnormal control of the alternative complement pathway is a risk factor for atypical HUS (aHUS) [8, 9]. These results led to the recent proposal to use the terms of ‘ADAMTS13-deficiency-related TMA’ and ‘complement-dysregulation-related TMA’ rather than the terms TTP and HUS [10].

In 2006, the European Paediatric Research Study group for HUS [11] published a revised classification of HUS, TTP and related disorders, based on the contemporary understanding of causation which can also be adopted for adult patients and is still accurate (summarized in table 1). In brief, patients can be classified as follows:
in the upper part, the cause is well established and in the lower part, disease or drug associations may be described but causation is not proven. The revised classification is in line with the idea that HUS can be caused by either, or both, an external environmental trigger and/or an intrinsic inherited risk factor and that in an individual patient the disease may have several etiologies. For example, a patient with complement factor H (CFH) gene mutation might present with an episode of HUS precipitated by infection, perhaps even classical enterohemorrhagic *E. coli* infection.

The aim of this review is to summarize the evident understanding of the pathophysiology of aHUS, the association with complement dysregulation, to discuss treatment guidelines and, last but not least, to work out the future treatment options.

**The Complement System and Its Regulation**

The complement system is an essential component of innate immunity with crucial roles in killing microorganisms, apoptotic cell clearance, bridging of innate and adaptive immunity and production of anaphylatoxins. Complement is activated by 3 pathways: the classical pathway, the lectin pathway and the alternative pathway [12]. These 3 pathways converge at the point of cleavage of C3 and have a common effector phase, initiating inflammation and microbial defense: (A) deposition of C3b molecules on the surface of microbes (opsonization), (B) formation of the terminal complex C5b–9 (MAC), which results in lysis of microbes or (C) releasing of anaphylactic products such as C5a (chemotaxis).

\[ \text{Fig. 2. Complement activation and control.} \text{ a} \text{ Activation of the complement system proceeds by 3 pathways: the classical, the lectin and the alternative pathway. Activation sets in motion a cascade by which inactive zymogens convert to active proteins and the generation of the C3 convertase of the classical/lectin and the alternative pathway (C3bBb) as the critical step in complement activation. All 3 pathways converge at the point of cleavage of C3 and have a common effector phase, initiating inflammation and microbial defense: (A) deposition of C3b molecules on the surface of microbes (opsonization), (B) formation of the terminal complex C5b–9 (MAC), which results in lysis of microbes or (C) releasing of anaphylactic products such as C5a (chemotaxis).} \text{ b} \text{ Covalent binding of C3b on foreign surfaces such as microbes leads to binding of CFB, which is then cleaved by factor D to form the C3 convertase of the alternative pathway C3bBb, providing exponential cleavage of C3b (the amplification phase of alternative complement pathway), and formation of the C5 convertase and of the MAC (the effector phase). Protection of host cells from formation of C3bBb on their surface is provided by soluble and membrane-associated complement regulatory proteins such as CFH, CFI and MCP, respectively. Dysfunction of regulatory proteins by so-called 'loss-of-function' gene mutations (labeled with †) or antibodies against CFH and gain-of-function mutations in the genes encoding CFB and C3 (labeled with *) lead to uncontrolled activation of the alternative complement pathway (described in detail in the text).} \]
tiated by the autoactivation of C3, the formation of a C3 convertase, followed by the generation of C3b. The C3b formed binds indiscriminately to surfaces as microbes and host cells. Covalent binding of C3b to pathogens leads to formation of further C3 convertases, providing the exponential cleavage of C3b (the amplification phase of complement activation) leading to MAC formation.

The uncontrolled activated complement system has devastating effects; therefore, host cells are protected from damage ‘to self’ and consumption of components of the complement system by soluble and membrane-associated regulatory proteins, which keep the system in track and provide local protection of host cells. This local control system ensures that activation is mainly targeted to quickly remove invading pathogens. The importance of these regulators is demonstrated by the fact that there are almost as many regulatory proteins as there are proteins in the complement activation cascade [12]. The complement regulators have 2 main mechanism of action: decay acceleration activity (i.e. decay of the C3 convertase) and cofactor activity. CFH is a fluid-phase regulator that has cofactor activity for the cleavage of C3b by complement factor I (CFI), and, in addition, has decay acceleration activity. CFH is a most important complement regulator. For its cleaving function, the fluid-phase serine protease CFI is dependent on cofactor activity. The membrane cofactor protein (MCP or CD46) is a resident transmembrane protein expressed on almost every human cell except erythrocytes. It is the second important cofactor for CFI for the cleavage of C3b and further promotes the decay of the C3 convertase. The activation and regulation of the alternative pathway is shown in figure 2b.

The impairment of the alternative pathway regulation leads to excessive liberation of different cleavage fragments such as the anaphylatoxins C3a and C5a and the unrestricted formation of the MAC. All components mediate different signaling pathways [13–16], leading to inflammation and platelet activation, and especially the MAC is capable of participating in the microangiopathic lesions of the kidney as shown in animal models [17–19].

**aHUS Associated with Gene Mutations in Complement Regulatory Proteins**

Nondiarrheal HUS or aHUS is a clinically defined form of TMA characterized by predominantly renal involvement, absence of Stx-producing bacteria as a triggering factor and is associated with relapses and a poor outcome. Overall, aHUS is less common than Stx-associated HUS and accounts for only 5–10% of all cases of HUS [9].

In 1981, Thompson and Winterborn [20] described the correlation of hypocomplementemia (i.e. reduced C3 level) and the involvement of the alternative complement pathway in the pathogenesis of aHUS. In 1998, Warwick er et al. [21] reported a link between aHUS and a region of chromosome 1q32 by genetic studies of 3 large families. This region contains a group of genes that have a central role in the regulation of complement activation: the regulators of complement activation (RCA) gene cluster. The innovative report of Warwicker et al. [21] and the subsequent descriptions of different mutations, all within genes encoding regulatory proteins of the alternative pathway, provided substantial evidence that uncontrolled activation of complement plays a central role in the pathogenesis of aHUS [8, 22–25].

Nowadays, aHUS can be described as a disease of alternative pathway dysregulation. There is a growing list of mutations and polymorphisms in genes encoding complement regulatory proteins that alone or in combination may lead to aHUS. The most frequently reported mutations are in the gene encoding CFH and account for 50–60% of cases associated with documented genetic abnormalities. Mutations in the genes encoding MCP and CFI are observed in approximately 20 and 10–15% of the overall disease-associated mutations, respectively (data from registries [22, 24, 26] and individual centers). Importantly, mutations in the genes encoding regulatory proteins are so called ‘loss-of-function’ mutations. There are now reports emerging that ‘gain-of-function’ mutations in the genes encoding factor B (CFB) or C3 have also been detected in a few patients with aHUS [27, 28]. These data expand our understanding of the critical role of the alternative pathway in the pathogenesis of aHUS. The incidence of mutations in proteins of the alternative pathway in patients with aHUS is illustrated in table 2.

**Complement Factor H**

Mainly synthesized by the liver, CFH is a single polypeptide chain glycoprotein of 150 kDa composed of 20 repetitive units of 60 amino acids, named short consensus repeats (SCR), arranged in a continuous fashion [29]. The CFH molecule includes different interaction sites for CFH and polyanions (fig. 3). The C3b binding site in SCR1–4 is the only site essential for the CFI cofactor activity of CFH. Similarly, the C3b/polyanions-binding site located within SCR19–20 is the most important site for preventing alternative complement pathway activation...
Fig. 3. Structure of CFH with the 20 SCR arranged in continuous fashion and its functional domains. CFH has 3 C3b-binding sites: SCR1–4, SCR12–14 and SCR19–20, respectively. Similarly, a total of 3 separate binding sites for heparin and sialic acid have been identified in SCR7, SCR13 and SCR19–20, respectively. The critical sites for cofactor activity/decay accelerating activity and cell surface regulation at the N- and C-terminal sites, respectively, are indicated.

Table 2. Incidence of mutations in proteins of alternative complement pathway in patients with aHUS

<table>
<thead>
<tr>
<th>Gene</th>
<th>Location</th>
<th>Frequency in aHUS, %</th>
<th>Ref. No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>CFH</td>
<td>RCA gene Chr 1</td>
<td>10–30</td>
<td>8, 22–24, 26, 34</td>
</tr>
<tr>
<td>MCP</td>
<td>RCA gene Chr 1</td>
<td>10–15</td>
<td>8, 22–24, 34, 41</td>
</tr>
<tr>
<td>CFI</td>
<td>Chr 4</td>
<td>5–10</td>
<td>8, 22, 34, 42, 43</td>
</tr>
<tr>
<td>CFB</td>
<td>Chr 6</td>
<td>0–3</td>
<td>27</td>
</tr>
<tr>
<td>C3</td>
<td>Chr 19</td>
<td>N/A</td>
<td>28</td>
</tr>
</tbody>
</table>

Chr = Chromosome; N/A = not available.

on host cells, showing distinct functional domains at the N- and C-terminal site of the CFH molecule, respectively [30]. Extrahepatic synthesis of CFH also occurs in a wide variety of cell types, such as glomerular mesangial cells, retinal pigment epithelial cells, peripheral blood lymphocytes, myoblasts, fibroblasts, umbilical vein endothelial cells, or neurons. The extrahepatic synthesis of CFH is interpreted as a mechanism to increase the local concentration of CFH for the protection of host cells from complement activation in sites of infection or inflammation.

In the human plasma, there are 6 proteins that are structurally related and cross-react immunochemically with CFH. Factor H-like protein FHL-1 is the product of alternative splicing of the gene-encoding CFH [31] and in addition there are 5 related proteins (CFHR1, CFHR2, CFHR3, CFHR4, CFHR5), that are encoded by 5 different genes [32]. These proteins are probably synthesized by the liver, but their concentrations in the plasma are much lower than that of CFH and their functional properties are not defined completely. The CFH gene is a member of the RCA gene cluster on chromosome 1q32 [33]. At present, 100 distinct CFH gene mutations or polymorphisms have been reported in aHUS patients [34]. All reported mutations were heterozygous, except in 15 patients (mostly from consanguineous families) with homozygous CFH deficiency [35] and a few cases of compound heterozygous mutations. The majority of mutations published up to now have been located within the C-terminal domain of the protein, particularly in SCR20 revealing a hot spot for mutations as shown in figure 4. Carriers of mutations in SCR19–20 express CFH molecules with a reduced ability to bind to surfaces, including polyanions of the endothelial cell and, thus, have limited capacity to protect host surfaces from alternative pathway activation but present normal regulatory (cofactor) activity in the fluid phase, i.e. in the plasma [36]. This limited complement regulatory capacity could lead to specific susceptibility to the development of aHUS as a situation of ‘autolesion’ caused by uncontrolled activation of complement in the kidneys.

It is interesting to note that only a few reported CFH gene mutations have been associated with quantitative CFH deficiency as defined by an antigenic plasma level below half normal; however, the antigenic level was not determined in every case [8].

In recent years, considerable evidence has been generated to support the hypothesis that both the membranoproliferative glomerulonephritis type II (MPGN2) and age-related macular degeneration (AMD) are further diseases caused by dysregulation of the alternative complement pathway. Several reports illustrate a remarkable genotype-phenotype correlation in which distinct genetic variations and mutations of CFH and related proteins predispose specifically to MPGN2, AMD or aHUS. In particular, the CFH His402 variant in SCR7 of CFH has consistently been shown to be associated with increased risk to develop AMD in numerous studies [37]. MPGN2 is associated with CFH gene mutations or autoantibodies directed against CFH but is also associated with autoan-
Fig. 4. The majority of the gene mutations associated with aHUS cluster in the C-terminal region of CFH. The structure of CFH is shown with the 20 SCR and the most representative mutations reported in the literature are indicated. The majority of mutations in the CFH gene are missense mutations, resulting in a single amino acid exchange.

tibodies directed against the C3 convertase of the alternative pathway called C3NeF. The coincidence of CFH deficiencies with strong complement activators such as C3NeF may be critical in the development of MPGN2 instead of aHUS. Interestingly, MPGN2 also associates with alleles of CFH and CFHR5 genes. A more extensive description of MPGN2 or AMD and the association with defective alternative pathway control have been given previously [38].

MCP (CD46)

MCP is a widely expressed transmembrane glycoprotein that inhibits complement activation on host cells by serving as a membrane-bound cofactor for the plasma serine protease CFI to cleave C3b and C4b. The N-terminal site of MCP consists of 4 SCR. This extracellular portion of MCP is followed by a hydrophobic transmembrane domain and a cytoplasmic anchor. Sites for C3b and C4b interactions have been mapped to SCR2, SCR3 and SCR4 [39]. The MCP gene is located within the RCA gene cluster on chromosome 1q32 and therefore was considered to be a candidate gene for mutations in patients with aHUS [40]. Richards et al. [41] identified for the first time functionally significant MCP gene mutations in 7 patients (3 pedigrees) presenting a family history of aHUS with a recessive form of inheritance. Since then, 25 disease-associated mutations due to homozygous, heterozygous or compound heterozygous forms of inheritance and 5 disease-associated polymorphisms have been identified [34]. Most of the mutations were found in the N-terminal SCR domains with the exception of 1 mutation found in the transmembrane domain. To illustrate this, figure 5 shows the location of the MCP gene mutations which have been identified in Italian and French cohorts of aHUS patients [22, 24]. Over 80% of all reported mutations caused a reduction in MCP surface expression, whereas small proportion resulted in only a functional defect. Further, in the French cohort, 2 individuals were described for the first time without any surface expression of MCP. Serum C3 levels in patients with MCP gene mutations were normal or slightly lower than normal, leading to the hypothesis that local dysregulation of the complement system in the kidney by reduced cofactor activity of mutant MCP predisposes to severe TMA in the renal vasculature.

Complement Factor I

CFI is a 2-chain serine protease in which the light chain carries the catalytic domain, while the function of the heavy chain, containing 2 low-density lipoprotein receptor domains and a CD5 domain (also called FIMAC), is unclear. CFI is predominantly synthesized by the liver and downregulates the alternative pathway by cleaving C3b, but is efficient only in the presence of cofactor pro-
teins (i.e. CFH and MCP). The CFI gene is located outside the RCA gene cluster on chromosome 4q25 [8].

In 2004, Frémeaux-Bacchi et al. [42] reported for the first time the clinical courses of 3 aHUS patients presenting with mutations in the CFI gene. Today, the database contains a total of 16 disease-associated mutations in the CFI gene and the majority of these mutations are within the catalytic domain of the light chain [34]. Further, most CFI gene mutations induce a lack of protein synthesis, and only few mutations have been associated with a functional deficiency. CFI gene mutations appear to be a less common cause of aHUS (between 5 and 10% of all aHUS patients) than are CFH and MCP gene mutations [22, 24, 42, 43].

**Recent Identification of Gain-of-Function Mutations**

Goicoechea de Jorge et al. [27] identified a subgroup of aHUS patients without mutations in the genes encoding complement regulatory proteins, showing persistent activation of the alternative pathway with very low serum levels of C3 and normal or elevated serum levels of C4. They found within that subgroup 2 families with heterozygous mutations in the gene encoding CFB. CFB is a zymogen that carries the catalytic site of the alternative pathway convertase C3bBb. Upon interaction with C3b, CFB is cleaved by complement factor D into 2 fragments, Ba and Bb. Ba is released and Bb remains bound to C3b, forming the convertase C3bBb, an active serine protease that cleaves additional C3 into C3b as shown in figure 2b. Functional analysis demonstrated that aHUS-associated CFB gene mutations are gain-of-function mutations that result in enhanced formation of C3bBb convertase or increased resistance to inactivation by complement regulatory proteins. Taken together, these data highlight that alternative pathway overactivation by gain-of-function mutations may lead to the pathogenesis of aHUS, although mutations in the CFB gene are rare, accounting for 0–3% of disease-associated mutations [34].

Further, the group of Frémeaux-Bacchi et al. [28] described in 2 independent cohorts (Newcastle and Paris) 9 novel distinct mutations of complement C3 in 14 patients with aHUS with persistently low serum C3 levels. Functional assays were performed with 7 expressed C3 mutants to assess the interaction of the secreted C3 mutants with MCP and demonstrated that 5 of these C3 mutants had decreased MCP binding and cofactor activity. Thus, the reduced interaction of these 5 of the 7 secreted C3 mutants with MPC is likely to induce gain of function relative to alternative pathway activation [28].

**Combined Mutations in aHUS, Other Susceptibility Factors and Genetic Variability**

Mutations in genes encoding complement proteins are identified in at least 50% of cases with familial or sporadic aHUS reported in the literature. It is important to note that about 10% of patients have combined mutations, especially of CFI gene mutations with either CFH or MCP gene mutations [22]. Penetrance of aHUS associated with mutations in genes encoding regulatory proteins or complement activators has been reported to be approximately 50% in all series, suggesting that the inheritance of a single mutation may be insufficient to cause aHUS by itself.

To identify additional aHUS susceptibility factors, the regulator genes have been analyzed further in genetic association studies [44, 45]. These and subsequent replication studies [27, 46–48] demonstrated 2 relatively frequent CFH and MCP gene alleles (CFH-H3 and MCPgaac haplotypes) that were significantly more frequent in aHUS patients (either with or without CFH, MCP, CFI, or CFB gene mutations) than in controls. Moreover, it could be shown that family members with complement regulatory or CFB gene mutations developing aHUS had inherited the allele carrying the genetic mutation from one parent and the allele carrying the disease-associated CFH and/or MCP gene haplotype from the other parent.
Interestingly, the healthy CFH, MCP, CFI or CFB gene mutation carriers in these families did not inherit the aHUS-associated CFH and/or MCP gene polymorphism. Although additional studies are needed to fully characterize the role of these CFH and MCP gene haplotypes, the association of CFH-H3 and MCPggaac haplotypes with aHUS is important because it indicates that polymorphism of the genes encoding CFH and MCP may predispose to aHUS in the absence of other mutations and that even in carriers of mutations, additional regulator gene variants may be needed for the development of the disease (‘multiple-hit hypothesis’) [38]. In practice, the implication of incomplete penetrance of the disease within families is that it is not possible for an individual family member presenting with a mutation and/or risk polymorphism to forecast the risk of the occurrence of aHUS. Even so, environmental triggers or precipitating events also appear to be a prerequisite for the development of the disease. In summary, mutations in genes encoding complement regulatory proteins or complement activators predispose to aHUS rather than they are causative per se.

Acquired Dysregulation of the Alternative Complement Pathway

In addition to gene mutations encoding complement regulatory proteins, CFH autoantibodies leading to an acquired functional CFH deficiency have been reported in aHUS patients, mostly in children [49–51]. The binding epitopes of the autoantibodies were localized to the C-terminal recognition region of CFH. This overlap with the majority of mutations within the C-terminal domain of the protein, particularly in SCR20, suggests similar functional consequences for the CFH autoantibodies and for the genetic mutations. Interestingly, individuals presenting with CFH autoantibodies are, with very few exceptions, homozygous for the deletion of the CFHR1 and CFHR3 genes. Whether the deletion of these genes and the presence of CFH autoantibodies are independent risk factors for aHUS remains unclear.

Clinical Characteristics of aHUS Associated with Alternative Complement Dysregulation

In the last decade, data from registries [22, 24, 26] and individual centers have made it possible to study the clinical characteristics of aHUS in accordance with the identified risk factors.

Triggering Events

It is worth noting that there is a high frequency of infectious triggering events in patients with aHUS, especially upper respiratory tract infections, fever and diarrhea [22, 24]. Diarrhea preceded aHUS in nearly 30% of patients from all subgroups, including Stx-associated bloody diarrhea in one child with an MCP gene mutation [24]. Harboring a MCP gene mutation could probably be a risk factor for a severe outcome of Stx-associated HUS, as a 4-year-old patient with an MCP gene mutation died from multivisceral involvement after Stx-associated HUS [52]. Another observation of an adult patient with a CFH gene mutation and severe diarrhea-positive HUS has also been reported [53].

Age at Onset of the Disease

Stx-associated HUS is the most common cause of acute renal failure in childhood [1]; on the other hand, aHUS may manifest at all ages but is more frequent in adolescent and adult patients [54]. Early age at onset in children appears to be characteristic of aHUS associated with CFH and CFI gene defects, while aHUS associated with MCP gene mutations is not seen before the age of 1 year [22, 24].

Familial aHUS

The incidence of familial aHUS ranged from less than 10% in the aHUS registry of the German-speaking countries [26] to 25% in the French [24] and 37% in the Italian aHUS registry [22], respectively, and the gender ratio was equilibrated. The frequency of familial aHUS is similar in the groups with CFH, MCP and CFI gene mutations and in the group with no mutation. Most frequently in familial aHUS, the disease occurs in siblings but may also be present in different generations. The absence of a family history of aHUS does not exclude the possibility of a genetic transmission of the disease.

Clinical Course and Outcome

Extrarenal involvement during HUS flares in aHUS patients with alternative complement dysregulation is very rare. Involvement of the central nervous system is found in around 30% of children with typical HUS and in these patients, it is the most common cause of mortality [55]. Concerning data from registries of aHUS patients [22, 24, 26] the clinical characteristics are best described in the French pediatric cohort (46 children). Fewer than 10% of these patients had extrarenal involvement (4 patients, including 1 with CFH mutation, and 3 with unexplained HUS had cerebrovascular events, 1 of these
Patients had pulmonary involvement, too [24]. Moreover, information obtained from literature research is poor. We found a single case report of a male child with congenital homozygote CFH deficiency who had an ocular hemorrhagic and ischemic involvement in one eye after 3 years of uneventful hemodialysis [56]. Ocular TMA has never been reported in patients with CFH mutations before but has recently been reported in a few pediatric patients with typical HUS [57]. Furthermore, in a clinicopathological study of 24 children with HUS (12 of them with typical presentation characterized by a diarrheal prodrome), involvement of the gut (severe colitis) has been reported in a few children leading to death during the acute phase of the disease as well as pancreatic islet cell necrosis leading to diabetes [58], but has never been reported in adult patients with aHUS associated with alternative complement dysregulation.

The overall prognosis of aHUS is poor with a high rate of mortality and recurrence. In the French pediatric cohort (46 children) and the Italian cohort (156 patients; about 30% adults) 9 and 10% of patients, respectively, died [22, 24]. A relapsing course of the disease may occur whatever the genotype underlying the disease as well as in patients with no identified gene mutation [22, 24, 26]. However, the number of relapses is significantly more important in the MCP gene-mutated and in mutation-negative patients. Relapses with complete recovery are mainly characteristic of patients with MCP gene mutations and some patients with no identified mutation. Poor clinical long-term outcome defined as end-stage renal disease (ESRD) is not only seen in patients with an identified gene mutation but also in mutation-negative patients. Relapses with complete recovery are mainly characteristic of patients with MCP gene mutations and some patients with no identified mutation. Poor clinical long-term outcome defined as end-stage renal disease (ESRD) is not only seen in patients with an identified gene mutation but also in mutation-negative patients [22, 24]. A relapsing course of the disease may occur whatever the genotype underlying the disease as well as in patients with no identified gene mutation [22, 24, 26].

Patients with CFH gene mutations tend to have the worst prognosis with early onset of the disease followed by a relapsing course, and 70% of cases progress to ESRD or die [22, 24]. Among the French children, 60% of those with CFH gene mutation had either died or reached ESRD by 1 year after disease onset in comparison to 32% in the group with no identified gene mutation and 0% of the MCP gene-mutated children [24]. Similar severe clinical outcome with progression to ESRD or death is seen in patients with CFI gene mutations; among the French and Italian cohorts 50 and 70%, respectively, reached ESRD [22, 24]. The clinical course and outcome of patients with gain-of-function mutations (i.e. CFB or C3 gene mutations) is not well documented in the literature.

**Investigation – A Diagnostic Algorithm**

Figure 6 illustrates a diagnostic algorithm which is intended to help physicians to distinguish between ‘atypical’ and more common forms of HUS based on consensus from expert opinion as evidence is lacking because of the rarity of these disorders. It offers an approach to the current revised classification of HUS, TTP and related disorders from the European Paediatric Research Study group for HUS [11], which helps us to identify the etiology of specific diagnostic subgroups of HUS. It is built up to recognize those cases of HUS that have etiologies other than enterohemorrhagic *E. coli* or *S. dysenteriae* type 1 infections (= post-diarrheal (D+) HUS) that are called ‘atypical’ (= aHUS) and mainly addresses the question: ‘How should I investigate a new patient with aHUS?’ Whether invasive *S. pneumoniae* infection-induced HUS should be called ‘atypical’ or not is still a matter of debate. For a comprehensible illustration in the diagnostic algorithm, this form of HUS is listed separately. Therapeutic strategies in patients with aHUS are discussed below.

Following the recognition of HUS, cases should be allocated to 1 of the 3 clinically recognizable patterns of disease presentation indicated in figure 6.

(A) Children older than 6 months presenting with diarrhea or bloody diarrhea require investigation to determine the cause of the gastrointestinal infection, including stool cultures, enhancement and selection techniques, gene probes for Stx subtypes and serotyping of the identified enterohemorrhagic enterobacteria, using local microbiological services.

(B) Patients with suspected invasive pneumococcal infection first of all need bacteriological confirmation by blood cultures. T antigen exposure on red blood cells strongly supports the diagnosis.

(C) All other cases of HUS can be regarded as aHUS and require full investigation (see section ‘Investigation – The Clinical Utility of Genetic Screening’ below).

**Notes on the Algorithm** (fig. 6)

(1) The cutoff point of 6 months is to some extent arbitrary, but exposure to Stx-producing organisms, i.e. enterohemorrhagic *E. coli* or *S. dysenteriae* type 1, is less likely before the age of 6 months. Between 1 and 5 years of age, the incidence of Stx (D+) HUS exceeds all other
Invasive Streptococcus pneumoniae infection (pneumonia, meningitis, septicemia, especially if there is loculated infection such as empyema or subdural collection)

Full investigation for alternative causes of HUS is required. Stool culture and investigation for Stx-producing enterobacteria is recommended routinely as unusual presentations occur.

Consider combined host and environmental factors; i.e., more than one aetiology is possible. See section "Investigation – the clinical utility of genetic screening”.

Fig. 6. Diagnostic algorithm: recognition of aHUS. Letters (A–C) and superscript numbers (1–5) refer to those used in the text.
causes [1]. On the other hand, aHUS may manifest at all ages. Concerning children, HUS which presents before 6 months of age or in adolescent patients is highly suspicious for aHUS triggered by disorders of complement regulation.

(2) (D+) HUS or HUS induced by pneumococcal infection is rapid in onset. Hemolytic anemia, thrombocytopenia and acute renal failure become apparent over a few days [1]. HUS induced by complement dysregulation or ADAMTS13 disorders can also abruptly occur. However, an insidious onset over more than 1 week, fluctuating clinical signs and laboratory parameters increase the likelihood of a noninfective cause [22, 24].

(3) HUS can follow transplantation of any organ [59, 60]. The role of drugs, especially calcineurin inhibitors, has been suspected but not proven [61]. HUS after renal transplantation raises the question of a host risk factor, whether or not the original cause of the patient’s ESRD was known to be HUS.

(4) In an outbreak of infection caused by Stx-producing enterobacteria, family members may develop HUS, either simultaneously (same source of infection) or a few weeks apart (secondary spread). These families do not require investigation beyond confirmation of the infection. By contrast, families with asynchronous HUS are very likely to have inherited risk factors and require full investigation (see also section ‘Clinical characteristics of aHUS associated with alternative complement dysregulation’).

(5) Stx-producing enterobacteria infection can cause HUS without diarrhea [1]. Also, urinary tract infection caused by Stx-producing enterobacteria is described in the literature [62]. Therefore, screening for Stx-producing organisms has to be done routinely for all patients who are recognized as having HUS.

Investigation – The Clinical Utility of Genetic Screening

As described above, gene mutations predispose to aHUS rather than they directly cause it. This means that for an individual with a gene mutation the risk of developing aHUS can only be estimated. However, as genotype-phenotype correlations can be seen in those individuals with gene mutations who have developed aHUS, it is clearly helpful to know by which complement mutation an individual is affected. Further, unaffected family members with a known complement mutation should be monitored during periods of increased risk (such as pregnancy and infections).

Considering the therapeutic implications, not only a comprehensive complement analysis in the plasma (i.e. complement C3, C4, CFH, CFI, and CFB antigenic levels), membrane expression of MCP in blood leukocytes and screening for anti-CFH antibodies in any individual with aHUS is mandatory, but also a genetic analysis of the genes encoding complement proteins.

A consensus agreement from the European Working Party on the Genetics of HUS has recently described a screening protocol for the detection of mutations in aHUS [63]. The National Institutes of Health-funded website GeneTests (http://www.genetest.org) provides information on laboratories which offer genetic screening in aHUS.

Concerning complement analysis, it is worth noting that if the C3 level is low, this indicates complement dysregulation but C3 levels may be normal in patients with complement dysregulation. Further CFH and CFI plasma concentrations may be normal in cases with mutations. Therefore, normal results of C3, CFH and CFI plasma concentrations do not exclude a complement disorder [34]. Investigation of ADAMTS13 activity is indicated routinely to distinguish between ‘ADAMTS13-deficiency-related TMA’ and ‘complement-dysregulation-related TMA’.

Therapeutic Strategies in Patients with aHUS

In practice, the complex laboratory investigations needed to confirm the etiology take several weeks and genotyping even longer. Therefore, although much progress in understanding the pathogenesis of the disease has been made in the last decade, initial treatment still has to be empirical. Up-to-date recommendations for clinical practice are summarized in table 3.

Plasma Therapy

There are many reports on plasma therapy in aHUS, but there are no clinical controlled trials. Nevertheless, plasma-based therapies remain the first-line treatment, although evidence is lacking. The recently published guidelines from the European Paediatric Study Group for HUS [64] argue for plasma exchange (PE), replacing it with fresh frozen plasma (FFP) or a standardized whole plasma product such as Octaplas® and recommend to start plasma therapy as early as possible, within 24 h of presentation, in parallel with conservative treatment (i.e. dialysis, transfusion, antihypertensive treatment, etc.). This is suggested on the basis that PE would remove mu-
Table 3. Up-to-date recommendations for the investigation and therapy of patients with aHUS

Investigation
Nondiarrheal or aHUS is a clinically defined form of TMA characterized by predominant renal involvement and the absence of Stx-producing bacteria as a triggering factor often has relapses and a poorer outcome.

Determination of complement C3, C4, CFH, CFI and CFB levels, expression of MCP and screening for anti-CFH antibodies are indicated for all patients with aHUS; normal C3 level does not exclude dysfunction of complement regulation (i.e. regulation of the alternative pathway).

Genotyping of genes encoding the complement regulators CFH, CFI and MCP and activators C3 and CFB is indicated for all patients with aHUS, even if plasma levels are normal.

The identified gene mutation has to be regarded as a risk factor for aHUS, not as the direct cause. Penetration of the disease is 50% in patients with a mutation in complement. Therefore, the risk of developing aHUS is difficult to predict in a family member presenting the mutation. Unaffected family members presenting with a mutation, however, should be monitored during periods of increased risk (such as pregnancy and infections).

A postdiarrheal onset of the disease does not exclude aHUS.

Therapy
PE (with FFP) should be started as early as possible. Benefit is expected mainly in CFH-mutated patients and in patients with anti-CFH antibodies; benefit is also likely in all other groups, except the MCP mutated subgroup, where spontaneous remission generally occurs.

The risk of graft loss due to recurrence is high in patients with CFH and CFI gene mutations, while it is very low in patients with MCP gene mutations.

Living donor transplantation is relatively contraindicated because of the risk of graft loss due to recurrence and in family members also because of the risk that donors themselves might have aHUS after donation as a result of unknown genetic factors shared with the recipient.

Kidney transplantation under pre-, intra-, and postoperative intensive plasma therapy may be successful in some patients.

Combined liver and kidney transplantation under pre- and intraoperative plasma therapy, and postoperative anticoagulation has been successful in a few patients with CFH gene mutations; this option will now have to be considered on an individual basis also for patients with CFI gene mutations, but assessment of the risk/benefit ratio requires careful and individual attention.

Hope for the future relies on therapies which could prevent ESRD, such as CFH concentrate or anti-C5 monoclonal antibodies.

Although it was recently established that the coagulation pathways themselves activate complement [67], routine use of anticoagulation is not recommended. However, low-molecular-weight heparin at prophylactic dosages and low-dose aspirin are recommended after combined liver and kidney transplantation (see below).

Transplantation
Renal transplantation for patients with aHUS cannot be considered without careful preliminary appraisal of the risk of graft loss as a result of disease recurrence. Genotyping the complement regulatory and activating genes now allows a more precise approach to evaluating the posttransplant risk of recurrence in aHUS patients. The risk of disease recurrence after renal transplantation in patients with aHUS has been reviewed [68].
Posttransplant Risk of Recurrence and Possible Prevention

While the risk of posttransplant recurrence is less than 1% in Stx-associated HUS patients [69], it is approximately 80% in CFH or CFI gene-mutated patients and most of them lost their graft within 1 year after recurrence [68]. As nonmutated MCP is acquired by the graft, no posttransplant recurrence is expected to occur in MCP gene-mutated patients and these patients can reasonably go to transplantation. Nevertheless, of the 10 MCP gene-mutated patients transplanted and published in the literature, 2 had posttransplant recurrence. One of them most probably had a second mutation in another regulator of the complement system [70]. In the other patient, endothelial microchimerism was suggested by the colonization of the graft endothelia by the recipient’s MCP-deficient cells [71]. The risk of recurrence in CFB or C3 gene-mutated patients is not well documented, as to date, there have been only a small number of patients with these genetic defects published in the literature. The risk of recurrence after transplantation in patients with no mutation is about 30% [68]. These findings underscore the clinical heterogeneity of outcome after renal transplantation in patients with aHUS and highlight the imperative for comprehensive complement analysis and genetic testing prior to renal transplantation in all patients with aHUS.

Avoidance of calcineurin inhibitors for immunosuppression does not lower the incidence of aHUS recurrence after transplantation. As frequency and duration of plasma therapy, therapeutic modalities (PE or FFP infusions) or volume of FFP infused or exchanged to prevent recurrence of aHUS after transplantation were highly variable in historical series, the effect of treatment is difficult to ascertain. Nevertheless, the efficiency of intensive prophylactic plasma therapy started before transplantation seems to have been demonstrated in the past [65] and is consistent with our own experience [72].

Taken into account the risk of graft loss due to recurrence, living donor transplantation is relatively contraindicated, but has to be considered individually and, in addition, in family members, the risk that donors themselves might have aHUS after donation, due to unknown genetic factors shared with the recipient, has to be considered [73].

Combined Liver and Kidney Transplantation

Both CFH and CFI are produced mainly in the liver, and successful liver transplantation would theoretically restore normal complement regulation and prevent disease recurrence. The first 3 combined liver-kidney and auxiliary liver transplantsations in children with CFH deficiency were disappointing, as 1 child had severe neurologic sequelae and died 3 years later, 1 child died short after transplantation from primary liver nonfunction and the child with the auxiliary liver transplantation developed posttransplantation lymphoproliferative disease and bacterial sepsis and died 11 months after auxiliary liver transplantation [74]. In the 1 child who died from primary liver nonfunction, autopsy of the liver showed diffuse thrombotic and ischemic lesions, most likely due to the thrombogenic effect of complement activation products deposited on the microvasculature of the liver after transplantation. Taking into account that liver transplantation might trigger intense local complement activation, these initial experiences suggested that liver transplantation should be performed under intensive pre- and perioperative plasma therapy to correct complement dysregulation. The first successful combined liver and kidney transplantation (a 5-year-old male child with CFH deficiency, who had lost a first graft due to recurrence at the age of 2) was reported in 2006 by Saland et al. [74]. The pivotal modification of the transplant procedure was to exchange plasma before transplantation with further plasma supplementation during surgery. This both increased the bioavailability of functional CFH during the critical period needed for the liver graft to recover synthetic functions and, at the same time, removed the endogenous mutant CFH. In addition, posttransplant anticoagulation with low-molecular-weight heparin at prophylactic dosages and low-dose aspirin was used in each of the successful procedures [74]. To date, 3 further successful combined kidney and liver transplantsations in patients with CFH gene mutations (2 children and 1 adolescent patient) have been done [74]. After the success of the initial combined transplantsations, a consensus conference on kidney and liver transplantation in aHUS was held in December 2007 and the recommendations have recently been published. In summary, these authors propose combined liver and kidney transplantation as the preferred option for aHUS patients with ESRD and mutations in the CFH gene and possibly also for patients with mutations in the CFI gene [74]. However, risks associated with this not yet established procedure of combined liver-kidney transplantation still remain, and assessment of the risk/benefit ratio requires careful and individual attention.
Way Forward – Future Therapeutic Options

It seems likely that specific treatments will be needed once the cause of aHUS has been identified. In patients with genetic CFH abnormalities it seems obvious to give normal CFH. A human plasma-derived CFH concentrate has been developed commercially with that intention, and it received the European orphan drug designation in January 2007. Substitution with CFH concentrate is a therapeutic option for patients with quantitative and functional CFH deficiency but it will have to be taken into account that such commercial concentrates have a short half-life. The same logic applies to aHUS associated with CFI gene mutations but a CFI concentrate is still not available.

Concerning the damage mediated by unregulated complement activation, monoclonal humanized antibodies against the key activating components of the final complement pathway such as C5 are a promising therapeutic option for patients with aHUS. Prevention of C5 activation has been shown to ameliorate spontaneous and experimental glomerulonephritis in CFH-deficient mice [75]. The long-term efficacy and tolerance of the anti-C5 monoclonal antibody eculizumab have been demonstrated in large cohorts of patients with paroxysmal nocturnal hemoglobinuria, a well-investigated complement disease [76–78]. To date, 2 cases of aHUS who were unresponsive to PE therapy have been published in the literature, presenting with hematologic and renal improvement after administration of eculizumab: an 18-month-old boy with congenital relapsing aHUS [79] and a 37-year-old woman with aHUS associated with a CFH and CFHR1 gene mutation and recurrence of aHUS 6 weeks after the second kidney transplantation [80]. These data show the positive effect of complement inhibition on the course of aHUS and provide impetus for the evaluation of eculizumab in controlled clinical trials.

Summary

aHUS is a disorder of alternative pathway dysregulation. A growing list of ‘loss-of-function’ mutations and polymorphisms in genes encoding regulatory proteins has been demonstrated to predispose to aHUS. Additionally, ‘gain-of-function’ mutations in complement activation genes have now been associated with aHUS. Recent advances in understanding the pathogenesis of aHUS have clinical significance in predicting renal recovery and transplant outcome. It is important to analyze the complement profile of patients with aHUS, including genetic screening as well. This may also provide opportunities for more specific treatments in the near future, as complement inhibition could represent a therapeutic target in patients with aHUS.

Acknowledgments

The authors wish to thank Prof. M. Mihatsch for the histological figure. During the past decade the field has progressed extensively and a large number of case reports and excellent papers about aHUS and complement dysregulation have been published. These data are summarized in this review; however, space restrictions allowed only a limited number of citations.

References


The minireview by Hirt-Minkowski and colleagues from Basel updates the reader on recent advances in the understanding of the genetics, pathophysiology and management of atypical hemolytic uremic syndrome. It sheds light on the rapidly expanding number of genetic mutations involving the complement system: complement factor H (CFH), membrane cofactor protein, complement factor I, complement factor B and C3 as well as thrombomodulin. Complement component activation, dysfunction or inactivation by autoantibodies seems to play a predominant role in the pathogenesis of this condition. The review also examines the rationale behind current and established therapies such as plasma exchange with fresh frozen plasma or plasma products such as Octaplas, namely the removal of dysfunctional complement components and/or autoantibodies and replacement with normal plasma components. It also explores new therapies aimed at modulating the complement system including anti-C5 monoclonal antibodies (eculizumab) and a human plasma-derived CFH concentrate. This is a rare disease where nephrology has made huge strides in the last decade. It exemplifies a condition where a better understanding of genetics sheds light on pathophysiology and leads to new therapies.

Editorial Comment

M. El Nahas, Sheffield

The minireview by Hirt-Minkowski and colleagues from Basel updates the reader on recent advances in the understanding of the genetics, pathophysiology and management of atypical hemolytic uremic syndrome. It sheds light on the rapidly expanding number of genetic mutations involving the complement system: complement factor H (CFH), membrane cofactor protein, complement factor I, complement factor B and C3 as well as thrombomodulin. Complement component activation, dysfunction or inactivation by autoantibodies seems to play a predominant role in the pathogenesis of this condition. The review also examines the rationale behind current and established therapies such as plasma exchange with fresh frozen plasma or plasma products such as Octaplas, namely the removal of dysfunctional complement components and/or autoantibodies and replacement with normal plasma components. It also explores new therapies aimed at modulating the complement system including anti-C5 monoclonal antibodies (eculizumab) and a human plasma-derived CFH concentrate. This is a rare disease where nephrology has made huge strides in the last decade. It exemplifies a condition where a better understanding of genetics sheds light on pathophysiology and leads to new therapies.